Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

The CCR5 delta-32 heterozygote subject is enrolled in Sangamo's clinical trial and, as part of the clinical trial protocol, is undergoing an ART treatment interruption , which is ongoing.

http://www.sys-con.com/node/2850652